A MedImmune shareholder has filed a class-action lawsuit against the company, its executives and directors, claiming the $15.6 billion buyout deal they hammered out with British-based AstraZeneca benefits them more than it does their public stockholders.
"Instead of attempting to obtain the highest value reasonably available for the company's stockholders, defendants spent a substantial effort tailoring the acquisition to meet the specific needs of AstraZeneca," shareholder Chris Larson says in the class-action lawsuit filed April 25 at Montgomery County Circuit Court, but disclosed in a MedImmune Inc. regulatory filing Tuesday evening.
More
No comments:
Post a Comment